239 related articles for article (PubMed ID: 27181566)
1. Safety and Efficacy of Bivalirudin in Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: From the REPLACE-2, ACUITY and HORIZONS-AMI Trials.
Giustino G; Mehran R; Bansilal S; Feit F; Lincoff M; Deliargyris EN; Kirtane AJ; Généreux P; Redfors B; Prats J; Bernstein D; Brener SJ; Skerjanec S; Lansky AJ; Francese DP; Dangas GD; Stone GW
Am J Cardiol; 2016 Jul; 118(1):6-16. PubMed ID: 27181566
[TBL] [Abstract][Full Text] [Related]
2. Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials.
Stone GW; Mehran R; Goldstein P; Witzenbichler B; Van't Hof A; Guagliumi G; Hamm CW; Généreux P; Clemmensen P; Pocock SJ; Gersh BJ; Bernstein D; Deliargyris EN; Steg PG
J Am Coll Cardiol; 2015 Jan; 65(1):27-38. PubMed ID: 25572507
[TBL] [Abstract][Full Text] [Related]
3. Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials.
Ndrepepa G; Neumann FJ; Deliargyris EN; Mehran R; Mehilli J; Ferenc M; Schulz S; Schömig A; Kastrati A; Stone GW
Circ Cardiovasc Interv; 2012 Oct; 5(5):705-12. PubMed ID: 23048052
[TBL] [Abstract][Full Text] [Related]
4. Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials.
Mehran R; Pocock S; Nikolsky E; Dangas GD; Clayton T; Claessen BE; Caixeta A; Feit F; Manoukian SV; White H; Bertrand M; Ohman EM; Parise H; Lansky AJ; Lincoff AM; Stone GW
JACC Cardiovasc Interv; 2011 Jun; 4(6):654-64. PubMed ID: 21700252
[TBL] [Abstract][Full Text] [Related]
5. Short- and long-term outcomes in diabetes patients undergoing percutaneous coronary intervention with bivalirudin compared with heparin and glycoprotein IIb/IIIA inhibitors: A meta-analysis of randomized trials.
Nairooz R; Sardar P; Amin H; Chatterjee S; Helmy T; Naidu SS
Catheter Cardiovasc Interv; 2015 Sep; 86(3):364-75. PubMed ID: 25914388
[TBL] [Abstract][Full Text] [Related]
6. Bivalirudin versus Heparin plus Glycoprotein IIb/IIIa Inhibitors in Women Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials.
Xu H; Wang B; Yang J; Ma S; Xie X
PLoS One; 2017; 12(1):e0169951. PubMed ID: 28095453
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis of randomized clinical trials comparing bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention and in patients with ST-segment elevation myocardial infarction.
Nairooz R; Sardar P; Amin H; Swaminathan RV; Kim LK; Chatterjee S; Feldman DN
Am J Cardiol; 2014 Jul; 114(2):250-9. PubMed ID: 24890986
[TBL] [Abstract][Full Text] [Related]
8. Impact of diabetes mellitus on the safety and effectiveness of bivalirudin in patients with acute myocardial infarction undergoing primary angioplasty: analysis from the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) trial.
Witzenbichler B; Mehran R; Guagliumi G; Dudek D; Huber K; Kornowski R; Stuckey TD; Fahy M; Parise H; Stone GW
JACC Cardiovasc Interv; 2011 Jul; 4(7):760-8. PubMed ID: 21777884
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial.
Rajagopal V; Lincoff AM; Cohen DJ; Gurm HS; Hu T; Desmet WJ; Kleiman NS; Bittl JA; Feit F; Topol EJ
Am Heart J; 2006 Jul; 152(1):149-54. PubMed ID: 16824845
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of bivalirudin monotherapy in patients with non-ST-segment elevation acute coronary syndromes with positive biomarkers undergoing percutaneous coronary intervention: a report from the Acute Catheterization and Urgent Intervention Triage Strategy trial.
Huang X; Chen S; Redfors B; Zhang Y; Souza CF; Mehran R; Bansilal S; Kirtane AJ; Brener SJ; Feite F; Dangas GD; Ben-Yehuda O; Stone GW
Coron Artery Dis; 2020 Jan; 31(1):59-65. PubMed ID: 31809479
[TBL] [Abstract][Full Text] [Related]
11. Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors.
Bangalore S; Toklu B; Kotwal A; Volodarskiy A; Sharma S; Kirtane AJ; Feit F
BMJ; 2014 Nov; 349():g6419. PubMed ID: 25389143
[TBL] [Abstract][Full Text] [Related]
12. Bivalirudin during primary PCI in acute myocardial infarction.
Stone GW; Witzenbichler B; Guagliumi G; Peruga JZ; Brodie BR; Dudek D; Kornowski R; Hartmann F; Gersh BJ; Pocock SJ; Dangas G; Wong SC; Kirtane AJ; Parise H; Mehran R;
N Engl J Med; 2008 May; 358(21):2218-30. PubMed ID: 18499566
[TBL] [Abstract][Full Text] [Related]
13. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial.
Han Y; Guo J; Zheng Y; Zang H; Su X; Wang Y; Chen S; Jiang T; Yang P; Chen J; Jiang D; Jing Q; Liang Z; Liu H; Zhao X; Li J; Li Y; Xu B; Stone GW;
JAMA; 2015 Apr; 313(13):1336-46. PubMed ID: 25775052
[TBL] [Abstract][Full Text] [Related]
14. Impact of Bleeding and Bivalirudin Therapy on Mortality Risk in Women Undergoing Percutaneous Coronary Intervention (from the REPLACE-2, ACUITY, and HORIZONS-AMI Trials).
Ng VG; Baumbach A; Grinfeld L; Lincoff AM; Mehran R; Stone GW; Lansky AJ
Am J Cardiol; 2016 Jan; 117(2):186-91. PubMed ID: 26704028
[TBL] [Abstract][Full Text] [Related]
15. Effect of Short Procedural Duration With Bivalirudin on Increased Risk of Acute Stent Thrombosis in Patients With STEMI: A Secondary Analysis of the HORIZONS-AMI Randomized Clinical Trial.
Tamez H; Pinto DS; Kirtane AJ; Litherland C; Yeh RW; Dangas GD; Mehran R; Deliargyris EN; Ortiz G; Gibson CM; Stone GW
JAMA Cardiol; 2017 Jun; 2(6):673-677. PubMed ID: 28249084
[TBL] [Abstract][Full Text] [Related]
16. Impact of antithrombotic treatment on short-term outcomes after percutaneous coronary intervention for left main disease: a pooled analysis from REPLACE-2, ACUITY, and HORIZONS-AMI trials.
Geisler T; Müller K; Karathanos A; Bocksch W; Gawaz M; Deliargyris E; Bernstein D; Lincoff AM; Mehran R; Dangas G; Stone GW
EuroIntervention; 2014 May; 10(1):97-104. PubMed ID: 24048204
[TBL] [Abstract][Full Text] [Related]
17. One-Year Mortality for Bivalirudin vs Heparins Plus Optional Glycoprotein IIb/IIIa Inhibitor Treatment Started in the Ambulance for ST-Segment Elevation Myocardial Infarction: A Secondary Analysis of the EUROMAX Randomized Clinical Trial.
Fabris E; Kilic S; Van't Hof AWJ; Ten Berg J; Ayesta A; Zeymer U; Hamon M; Soulat L; Bernstein D; Anthopoulos P; Deliargyris EN; Steg PG
JAMA Cardiol; 2017 Jul; 2(7):791-796. PubMed ID: 28273285
[TBL] [Abstract][Full Text] [Related]
18. An updated comprehensive meta-analysis of bivalirudin vs heparin use in primary percutaneous coronary intervention.
Shah R; Rogers KC; Matin K; Askari R; Rao SV
Am Heart J; 2016 Jan; 171(1):14-24. PubMed ID: 26699596
[TBL] [Abstract][Full Text] [Related]
19. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial.
Stone GW; White HD; Ohman EM; Bertrand ME; Lincoff AM; McLaurin BT; Cox DA; Pocock SJ; Ware JH; Feit F; Colombo A; Manoukian SV; Lansky AJ; Mehran R; Moses JW;
Lancet; 2007 Mar; 369(9565):907-19. PubMed ID: 17368152
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of bivalirudin monotherapy in patients with diabetes mellitus and acute coronary syndromes: a report from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.
Feit F; Manoukian SV; Ebrahimi R; Pollack CV; Ohman EM; Attubato MJ; Mehran R; Stone GW
J Am Coll Cardiol; 2008 Apr; 51(17):1645-52. PubMed ID: 18436116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
